Audiometric Profile of Patients on Treatment for Drug-Resistant Pulmonary Tuberculosis in Owerri, South-East Nigeria.
DOI:
https://doi.org/10.14738/bjhmr.102.14144Keywords:
Drug-resistant, Tuberculosis, Ototoxic, Audiometry, OwerriAbstract
Background: Tuberculosis is an existential medical challenge in certain parts of the world necessitating global efforts. Perhaps more challenging is the treatment of drug-resistant forms of the disease as this requires use of second line drugs, predominantly potentially ototoxic aminoglycosides. The hearing impairment so caused, besides constituting social disability, can impair compliance and have far-reaching consequences. This study aimed at assessing the hearing patterns of patients on treatment for drug-resistant pulmonary tuberculosis to determine if, and to what extent their treatment affected their hearing status.
Patients and method: The study was an 18-month prospective analysis of consecutive newly diagnosed drug-resistant pulmonary tuberculosis patients in a tertiary hospital in Owerri, Nigeria. Baseline audiometry was conducted on the patients with subsequent monthly audiometry for 3 months during treatment. A control group drawn from normal population and matched for age and sex with the study group was recruited and audiometry performed on the participants in similar pattern. The audiometric patterns of both groups were analyzed and compared using Statistical Package for Social Sciences (SPSS) version 20.0 software for Windows. Statistical significance was set at p< 0.05.
Results: Thirty-eight (38) patients treated for drug-resistant pulmonary tuberculosis completed the study alongside thirty-eight (38) control subjects with M:F ratio was 1.53:1. The baseline prevalence of hearing impairment of any sort was 73.7% and 68.4% among the test and control groups respectively, whereas after three months it was 89.5% and 68.4% respectively. The cumulative incidence of hearing loss over three months was 15.8% and 0% respectively. This difference was statistically significant.
Conclusion: Treatment of drug-resistant tuberculosis with second line drugs can lead to significant hearing impairment within the first three months of treatment.
References
Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organisation. Tubercle. 1991;71:1-6.
World Health Organisation (WHO). Global tuberculosis report 2016. Executive summary. www.who.int/tb/publications/global_report/en/executivesummary. Assessed 03/05/2017.
World Health Organization (WHO). Global tuberculosis report 2016. Annex 4: TB burden estimates, notifications and treatment outcomes for individual countries and territories, WHO regions and the world. www.who.int/tb/publications/global_report/en/annex4. Assessed 04/05/2017.
World Health Organization (WHO). Guidelines for programmatic management of drug-resistance: Emergency update 2008. Geneva. World Health Organization; 2008.(WHO/HTM/TB/2008.402.)
Gregory LC, Loven M, Greg S, Keertan D. The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis. 2014; 6(3):186-195.
Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012 May 8;
Ruhl DS, Cable BB, Martell DW. Medication associated with hearing loss: 25 years of medical malpractice cases in the United States. Otolaryngol Head Neck Surg. 2014; 151(3):431-7.
American Speech-Language-Hearing Association (ASHA) Guidelines for the audiological management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36 Suppl 12: 11-19.
Zhang X, Anderson AB, Lillebaek T, Kamper-Jorgensen Z, Ostergaard V, Ladefoged K et al. Effect of sex, age and race on clinical presentation of tuberculosis: a 15 years population based study. Am J Trop Med Hyg. 2011;85(2):285-90.
Sogebi OA, Fadeyi MO, Adefuye BO, Soyinka FO. Hearing threshold in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations. J Bras Pneumol. 2017;43(3):195-201.
Ramma L, Ibekwe TS. Cochleovestibular clinical findings among drug resistant tuberculosis patients in therapy- a pilot study. Int Arch Med J. 2012; 3:682-5.
Duggal P, Sarkar M. Audiological monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long-term follow up. BMC Ear Nose Throat Disord. 2007;7(5):815-7.
Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning disability and health. Bull World Health Organ. 2019;97(10):725-728.
Ibekwe MU, Nwosu C. Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Med J. 2016; 10:97-101.
Vasconcelos KA, Kritski A, Ruffino-Netto A, Frota S, Antonio M. Audiometric evaluation of patients treated for Pulmonary tuberculosis. J Bras Pneumol. 2012;38(1):180-6.
Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HGM, Mantel-Teeuwsse AK. Comparing Amikacin and Kanamycin induced hearing loss in multidrug resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharm Toxicol. 2015;16:36-7.
Appana D, Joseph L, Paken J. An audiological profile of patients infected with multidrug resistant tuberculosis at a district hospital in KwaZulu-Natal. S Afr J Commun Dis. 2016;63(1):154-7.
Peloquin CA, Berning SE, Nitta AT. Aminoglycoside toxicity: daily versus thrice weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:1538-44.
Seddon JA, Godfrey-Faussett, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Resp J. 2012;40:1277-86.
Jain S, Aftab M, Singh SP, Dubey AK, Upadhyay VP, Singh HN. Ototoxic effect of anti-tubercular treatment on multi-drug resistant tuberculosis patients. Int J Otorhinolaryngol Head Neck Surg. 2020;6(1):241-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Nduagu, Samuel Uchechukwu, Onyeagwara, Ngozi Carol
This work is licensed under a Creative Commons Attribution 4.0 International License.
